Farxiga clinical uses
Pro Research Analysisby 
Searched over 200M research papers
Farxiga (Dapagliflozin) Clinical Uses: Type 2 Diabetes Treatment
Farxiga (dapagliflozin) is primarily used to manage type 2 diabetes. It works by inhibiting the sodium-glucose cotransporter-2 (SGLT2) in the kidneys, which reduces glucose reabsorption and increases glucose excretion in urine, leading to lower blood sugar levels. Farxiga can be used alone or in combination with other antidiabetic medications, including metformin, insulin, and other oral agents. It is effective in reducing glycosylated hemoglobin (HbA1c), fasting plasma glucose, and body weight, and it has a low risk of causing hypoglycemia when not combined with insulin or insulin secretagogues. However, it is not recommended for patients with moderate or severe renal impairment or for those with type 1 diabetes or end-stage chronic kidney disease Siddiqui2024Plosker2014Vivian2015+2 MORE.
Farxiga for Heart Failure: Reduced and Preserved Ejection Fraction
Farxiga has been approved for treating heart failure with reduced ejection fraction (HFrEF), both in patients with and without type 2 diabetes. Clinical trials have shown that dapagliflozin significantly reduces the risk of cardiovascular death and hospitalization for heart failure when added to standard therapy, regardless of diabetes status. The benefits are consistent across different heart failure medications and patient backgrounds. More recently, Farxiga has also been approved for heart failure with preserved ejection fraction (HFpEF), expanding its role in cardiac care Siddiqui2024Blair20216+2 MORE.
Farxiga in Chronic Kidney Disease
Farxiga is also approved for the treatment of chronic kidney disease (CKD). It helps slow the progression of kidney disease and reduces the risk of kidney failure, cardiovascular death, and hospitalization for heart failure in patients with CKD, regardless of whether they have diabetes. This makes Farxiga a valuable option for patients with both diabetes and kidney disease, as well as those with CKD alone .
Safety, Tolerability, and Contraindications
Farxiga is generally well tolerated, with the most common side effects being genital infections, urinary tract infections, and, rarely, Fournier’s gangrene. It is contraindicated in patients with type 1 diabetes and end-stage chronic kidney disease. There is a low risk of hypoglycemia unless used with insulin or insulin secretagogues. Some studies have noted a potential imbalance in bladder cancer cases, but ongoing research is needed to clarify this risk Siddiqui2024Plosker2014Vivian2015+1 MORE.
Conclusion
Farxiga (dapagliflozin) has evolved from a diabetes medication to a versatile drug with proven benefits in type 2 diabetes, heart failure (both HFrEF and HFpEF), and chronic kidney disease. Its unique mechanism, favorable safety profile, and broad clinical applications make it an important option for improving outcomes in these patient populations Siddiqui2024Plosker2014Vivian2015+6 MORE.
Sources and full results
Most relevant research papers on this topic
Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Dapagliflozin, an SGLT2 inhibitor, improves glycemic control in adults with type 2 diabetes by inhibiting renal reabsorption of glucose, offering a novel treatment option independent of insulin secretion or action.
DOI